Qualigen Therapeutics, Inc.

Qualigen Therapeutics is a clinical-stage therapeutics company focused on developing treatments for rare adult and pediatric cancers.

[Qualigen Therapeutics, Inc. @QualigenTx]

We are grateful for the support of our employees, partners, investigators, patients and families who are all working together to advance new treatments for challenging diseases. We can't do it without you. Wishing everyone the best this Holiday Season. #driventodeliver #oncology

[Qualigen Therapeutics, Inc. @QualigenTx]

Every moment counts for the nearly 100,000 people in the US living with pancreatic cancer.
We are proud to obtain Orphan Drug Designation from the FDA for QN-302 toward a potential treatment for pancreatic cancer.
Learn about World Pancreatic Cancer Day: https://t.co/zlDjxLARpO

[Qualigen Therapeutics, Inc. @QualigenTx]

We initiated dosing of three patients in our first cohort for our Phase 1a clinical trial. Read about our progress in our Third Quarter To Date Corporate Update: https://t.co/eptqXcntXZ #driventodeliver #oncology

[Qualigen Therapeutics, Inc. @QualigenTx]

Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors #driventodeliver #oncology #clinicaltrials https://t.co/GFTrK28wvB

[Qualigen Therapeutics, Inc. @QualigenTx]

Qualigen Therapeutics is attending the BIO Investor Forum Oct 17th-18th in San Francisco. Our Chief Medical Officer Tariq Arshad will be giving a presentation at 2pm PT tomorrow. Please join us! https://t.co/akk96F7xRm

[Qualigen Therapeutics, Inc. @QualigenTx]

Our Chief Medical Officer Dr. Tariq Arshad presented two posters on potential clinical #biomarkers and transcriptomic data associated with QN-302’s mechanism of action at the AACR Special Conference: Pancreatic Cancer in Boston! #oncology #driventodeliver https://t.co/wA3Fbf4hty

[Qualigen Therapeutics, Inc. @QualigenTx]

Our Chief Medical Officer Dr. Tariq Arshad is attending the 5th Annual RAS-Targeted Drug Development Summit held Sept 26-28th in Boston. Our goal is to develop effective therapies for RAS-driven cancers, which make up ~25% of all cancers #oncology https://t.co/nGCcB742kZ

[Qualigen Therapeutics, Inc. @QualigenTx]

We are excited to continue our partnership with @TD2_Oncology on our Phase 1 clinical trial for QN-302. We anticipate to enroll our first patient in the second half of 2023. #oncology #phase1

[Translational Drug Development (TD2) @TD2_Oncology]

We are excited to be an important partner with Qualigen Therapeutics in their Phase I clinical development. Moving new therapies to the patients who need it the most. #oncology #drugdevelopment https://t.co/06VtmjKUpl

[Translational Drug Development (TD2) @TD2_Oncology]

We are excited to be an important partner with Qualigen Therapeutics in their Phase I clinical development. Moving new therapies to the patients who need it the most. #oncology #drugdevelopment https://t.co/06VtmjKUpl

[Qualigen Therapeutics, Inc. @QualigenTx]

Qualigen Therapeutics, Inc. Reports Financial Results and Provides Corporate Update #driventodeliver #oncology #ClinicalTrials
https://t.co/C2GudPPanM

[Qualigen Therapeutics, Inc. @QualigenTx]

Listen to our SVP and Chief Medical Officer Tariq Arshad discuss the promise of pan-RAS inhibitors as an approach to potentially treat multiple types of RAS-driven cancers, on the "Empowered Patient Podcast" #driventodeliver #oncology @KarenJagoda https://t.co/xydQFmpOAe

[UCL Technology Fund @UCLTF]

A tumour-busting drug developed at UCL @School_Pharmacy, with backing from UCLTF, is set to be trialled in patients following U.S regulatory approval. @AlbionVC @UCL_Business @QualigenInc

Discover more: https://t.co/va44cc3Nbt

[Qualigen Therapeutics, Inc. @QualigenTx]

Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors. #oncology #clinicaldevelopment #driventodeliver
https://t.co/W09gpB0HTA

[Qualigen Therapeutics, Inc. @QualigenTx]

All cash deal for FastPack® diagnostics business solidifies and supports Qualigen’s strategic priority on therapeutics. #driventodeliver #oncology
https://t.co/OLsN29XqJ1

[Qualigen Therapeutics, Inc. @QualigenTx]

Qualigen Therapeutics delegates @DrewHertig and @drtariqarshad1 are looking forward to connecting in 1:1 partnering at BIO International Convention in Boston this week! #StandUpForScience #BIO2023

[Qualigen Therapeutics, Inc. @QualigenTx]

A snapshot from #asco2023 this morning where Qualigen Therapeutics Chief Medical Officer, Dr. Tariq Arshad presented data on our Pan-RAS platform. https://t.co/QAnWNjrUAl #oncology #pancreaticcancer #cancerresearch #ras

[Qualigen Therapeutics, Inc. @QualigenTx]

Join us @ASCO. 8-11am in Hall A. Learn about Qualigen’s Pan-RAS platform. Here is some info on our posters and presentations. https://t.co/UCj6bcD9KL https://t.co/XL4rZjNXEU https://t.co/3a82lmyvQd #ASCO23 #oncology #pancreaticcancer #breastcancer #cancerresearch #ras

[Qualigen Therapeutics, Inc. @QualigenTx]

Dr. Stephen Neidle, UCL Professor and QN-302 inventor, presented yesterday at the London Pancreas Workshop 2023, which focused on pancreatic cancer research. Dr. Neidle has played a key role in the progress of the QN-302 program. #pancreaticcancer #oncology

[Qualigen Therapeutics, Inc. @QualigenTx]

Dr. Tariq Arshad and Dr. Stephen Neidle ready to present data on G4-Selective Transcription Inhibitor #QN-302 as a potential treatment for pancreatic cancer during @AACR in Orlando. https://t.co/H60JEApaWV #driventodeliver #oncology #AACR2023

[Qualigen Therapeutics, Inc. @QualigenTx]

Learn about Orphan Drug Designation (ODD) and QN-302, a G-Quadruplex (G4) transcription inhibitor for the intended indication of pancreatic cancer. https://t.co/8Zvf7YW9Pp #orphandrug #driventodeliver #cancerresearch #pancreaticcancer.